openPR Logo
Press release

Histone Deacetylase 6 Market Research Report -Pipeline Review, H2 2017

Histone Deacetylase 6 Market Research Report -Pipeline Review,

"The Latest Research Report Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Histone Deacetylase 6 Market

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 6-Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1339570

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 14 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Toxicology, Dermatology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Melanoma, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Alzheimer's Disease, Autoimmune Disorders, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colon Tumor, Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Endometrial Cancer, Fallopian Tube Cancer, Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Inflammation, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Multiple Sclerosis, Myelodysplastic Syndrome, Neuroblastoma, Neurodegenerative Diseases, Neurology, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Polycystic Kidney Disease, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sepsis, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Lupus Erythematosus and Thyroid Cancer.

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339570/histone-deacetylase-6-protein-phosphatase-1-regulatory-subunit-90-or-hdac6-or-ec-35198-pipeline-review-h2-2017-market-research-reports.pdf

Furthermore, this report also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1339570

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Overview 9
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 17
Products under Development by Universities/Institutes 24
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Therapeutics Assessment 26
Assessment by Mechanism of Action 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Companies Involved in Therapeutics Development 31
Celgene Corp 31
Chong Kun Dang Pharmaceutical Corp 32
Curis Inc 33
HitGen LTD 33
Kancera AB 34
Karus Therapeutics Ltd 34
Medivir AB 35
Merck & Co Inc 35
Millennium Pharmaceuticals Inc 36
OnKure Inc 37
Quimatryx SL 37
Shuttle Pharmaceuticals LLC 37
Sigma-Tau SpA 38
SK Biopharmaceuticals Co Ltd 38
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Drug Profiles 39
ACY-1083-Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ACY-738-Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ACY-775-Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Histone Deacetylase 6 Market Research Report -Pipeline Review, H2 2017 here

News-ID: 761983 • Views:

More Releases from MarketResearchReports.biz

Hydro-flyers Market: Moving Towards a Brighter Future
Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in
Outdoor Floodlights: Technology and Market Dynamics
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume
Snow Helmets Market Future Prospects and Regional Outlook
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is

All 5 Releases


More Releases for Histone

Global Histone Deacetylase Inhibitors Market Research Report
This report studies the global Histone Deacetylase Inhibitors market status and forecast, categorizes the global Histone Deacetylase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report 4SC AG Acetylon Pharmaceuticals Celleron Therapeutics Chroma Therapeutics CrystalGenomics Curis MEI Pharma Mirati Therapeutics Novartis
Histone Methyltransferases Market Growth Analysis 2019
Histones are the major protein constituents of eukaryotic nucleus. Histone methyltransferases catalyzes the transfer of methyl group to lysine and arginine residues of the histone protein. It catalyzes the reaction with the help of SN-2 mechanism where transfer of methyl group from S Adenosyl Methionine to amino group of target lysine takes place. There are seven histone methyltransferase includes EZ, SET1, SET2, SMYD, SUV39, SUV4-20 and RIZ. The main function
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase Inhibitors Market & Pipeline Insight2015
Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline …
The latest report Histone Deacetylase 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development